TransCelerate Overview - Value of Safety Information Data Sources Initiative
BioRealm Press Release 2015
1. Overview
News & Events
Investors
SEC Filings
Stock Information
Press Releases
Event Calendar
Leadership
Webcast Archive
Stockholder FAQs
Analyst Coverage
E-mail Alerts
Information Request
Annual Meeting Materials
Stockholder Electronic
Delivery
Contact Us
Toolkit
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Stock Quote
Home > About Affymetrix > Investors > Press Release
Press Release
View printer-friendly version << Back
Genotyping Begins on NIDA’s Biorepository of Over 50,000 Samples – Affymetrix, BioRealm, and RUCDR Infinite
Biologics Team up to Help Study the Genetics of Addiction
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 7, 2015-- Affymetrix, Inc. (NASDAQ:AFFX), BioRealm, LLC, and RUCDR Infinite
Biologics today announced a broad strategic alliance. This alliance will leverage BioRealm's SmokeScreen platform to genotype
the National Institute on Drug Abuse (NIDA) biorepository of more than 50,000 samples, collected from human subjects studied
in NIDA-funded research. NIDA preserves these samples in a biorepository at RUCDR Infinite Biologics, on the campus of Rutgers
University. The biorepository is maintained by RUCDR Infinite Biologics and in part through collaboration with the BioProcessing
Solutions Alliance which was created by RUDCR Infinite Biologics and BioStorage Technologies, the global leader in comprehensive
sample management.
Once the genetic information contained in these samples is made available to researchers, it will be extremely valuable for
studying the link between genetic variations and addiction. Detailed genetic information might, for example, be used by
researchers exploring how genetics influences patients’ individual responses to treatment approaches.
To date, the genetic information contained in these samples has been focused on specific targets and not collectively analyzed.
This strategic alliance makes it possible, for the first time ever, to cost-efficiently analyze this valuable information. The genetic
information will be obtained by using BioRealm’s SmokeScreen array, developed in conjunction with NIDA’s Genetics Consortium
and Affymetrix. SmokeScreen array is a genome-wide array with research-driven focus on more than 1,000 addiction-related
genes.
BioRealm’s Co-Founder Dr. James Baurley remarked, “We are extremely honored to have the help and support of Affymetrix and
RUCDR. Our SmokeScreen technology provides a suite of genomic research tools to scientists working on addiction – one of the
biggest public health threats. Because of our partners’ confidence in our technology, it will be made available to scientific teams
around the world who are working on these critical health issues.”
®
®
®
®
JP CNHomeHome ProductsProducts BrandsBrands CommunityCommunity SupportSupport Partners & ProgramsPartners & Programs About AffymetrixAbout Affymetrix CareersCareers NetAffxNetAffx
Convert html to pdf online with PDFmyURL
2. Security
AFFX (Common Stock)
$13.85
(0.00%
Current Day's High
13.86
Current Day's Low
13.83
Current Day's Volume
3,789,397
Last Trade
Jan 22 16 4:00 p.m. ET
Exchange
NASDAQ
The stock price
performance shown on
the quote above is not
necessarily indicative of
future price performance
RUCDR Infinite Biologics’ Chief Operating Officer and Director of Technology Development Dr. Andrew Brooks said, “Because of the
SmokeScreen array, we have the ability to reveal genetic information previously hidden in NIDA's samples. We have great
confidence in SmokeScreen ‒ it is a validated platform that will become a crucial tool in advancing addiction research and moving
the field towards personalized treatment.”
According to Dr. Frank R. Witney, President and Chief Executive Officer of Affymetrix, “We are excited to be part of BioRealm’s
vision of improving human health by providing insight into the genetics of tobacco-related illness. It was a pleasure to work with
BioRealm’s team of dedicated scientists to co-develop this cutting-edge technology.”
About BioRealm LLC
BioRealm, a life sciences company headquartered in Monument, Colorado, uses novel technology to provide end-to-end services
for researchers and product development teams, including study design, data management, and data analysis. BioRealm’s cutting-
edge products and technologies support the research process, from hypothesis to conclusion. BioRealm’s SmokeScreen platform
provides researchers with unique insight into the genetics of addiction, smoking behavior, and treatment approaches. Read more
at http://biorealmresearch.com/.
About RUCDR Infinite Biologics
RUCDR Infinite Biologics offers a complete and integrated selection of biological sample processing, analysis and biorepository
services to government agencies, academic institutions, foundations, and biotechnology and pharmaceutical companies within the
global scientific community. RUCDR provides DNA, RNA, and cell lines with clinical data to hundreds of research laboratories for
studies on mental health and developmental disorders, drug and alcohol abuse, diabetes and digestive, liver, and kidney diseases.
A unit of Rutgers University’s Human Genetics Institute of New Jersey, RUCDR is the world’s largest university-based
biorepository. In 2012, a Bioprocessing Solutions Alliance was created between RUCDR and BioStorage Technologies to provide
research companies and organizations with a state-of-the-art scientific and technology infrastructure for the delivery of advanced
sample bioprocessing and biobanking solutions. Read more at www.rucdr.org.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level,
facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. Affymetrix
provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than
2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published
citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in
Cleveland, Ohio, San Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees worldwide and maintains sales and
distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit
www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the
®
®
®
Convert html to pdf online with PDFmyURL
